A Novel MSE Score to Predict rHCC Patients

Develop and validate a novel scoring system based on pathological factors to predict the postoperative survival of patients with rHCC.Patients with rHCC who underwent hepatectomy were recruited from two hospitals.Exploring whether this scoring system is related to prognosis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HCC

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

a diagnosis of ruptured tumor confirmed by enhanced computed tomography (CT) and/or abdominal magnetic resonance imaging (MRI),
a diagnosis of HCC made by two experienced pathologists

Exclusion criteria

extrahepatic HCC metastasis
death within 1 month after surgery

Treatment and study plan

Hepatectomy

Procedure

Primary outcomes

overall survival

Time frame: 2010-2022

Time from the first postoperative day to survival at the last follow-up

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Registry information

Official study title

A Novel MSE Score to Predict the Postoperative Prognosis of Patients With Ruptured Hepatocellular Carcinoma

Important dates

Study start: 2010
Primary completion: 2017
Study completion: 2022
First posted: Jul 11, 2022
Registry last updated: Jul 11, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed